Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer

Alexander, Angela and Karakas, Cansu and Chen, Xian and Carey, Jason P.W. and Yi, Min and Bondy, Melissa and Thompson, Patricia and Cheung, Kwok-Leung and Ellis, Ian O. and Gong, Yun and Krishnamurthy, Savitri and Alvarez, Ricardo H. and Ueno, Naoto T. and Hunt, Kelly K. and Keyomarsi, Khandan (2017) Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget . ISSN 1949-2553

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under Licence Creative Commons Attribution.
Download (4MB) | Preview

Abstract

Inflammatory breast cancer (IBC) is a virulent form of breast cancer, and novel treatment strategies are urgently needed. Immunohistochemical analysis of tumors from women with a clinical diagnosis of IBC (n = 147) and those with non-IBC breast cancer (n = 2510) revealed that, whereas in non-IBC cases cytoplasmic cyclin E was highly correlated with poor prognosis (P < 0.001), in IBC cases both nuclear and cytoplasmic cyclin E were indicative of poor prognosis. These results underscored the utility of the cyclin E/CDK2 complex as a novel target for treatment. Because IBC cell lines were highly sensitive to the CDK2 inhibitors dinaciclib and meriolin 5, we developed a high-throughput survival assay (HTSA) to design novel sequential combination strategies based on the presence of cyclin E and CDK2. Using a 14-cell-line panel, we found that dinaciclib potentiated the activity of DNA-damaging chemotherapies treated in a sequence of dinaciclib followed by chemotherapy, whereas this was not true for paclitaxel. We also identified a signature of DNA repair–related genes that are downregulated by dinaciclib, suggesting that global DNA repair is inhibited and that prolonged DNA damage leads to apoptosis. Taken together, our findings argue that CDK2-targeted combinations may be viable strategies in IBC worthy of future clinical investigation.

Item Type: Article
Keywords: Cell cycle, Inflammatory breast cancer, CDK2, Cyclin E, Treatment
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine
Identification Number: https://doi.org/10.18632/oncotarget.14689
Depositing User: Eprints, Support
Date Deposited: 26 Jan 2017 13:39
Last Modified: 27 Jan 2017 02:03
URI: http://eprints.nottingham.ac.uk/id/eprint/40113

Actions (Archive Staff Only)

Edit View Edit View